Maria
Vieito Amor
Publications (21) Maria Vieito Amor publications
2023
-
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Med, Vol. 4, Núm. 10, pp. 710-727.e5
-
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
Nature communications, Vol. 14, Núm. 1, pp. 1359
-
Review of the remission and management of a cancer related pain population to a pain unit. What can we improve?
Revista de la Sociedad Espanola del Dolor, Vol. 30, Núm. 1, pp. 7-14
2022
-
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
ESMO Open, Vol. 7, Núm. 5
-
Non-invasive biomarkers for response and survival prediction in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICIs)
European Journal of Cancer, Vol. 174, pp. S70
-
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
Neuro-Oncology Advances, Vol. 4, Núm. 1
2021
-
Adaptation of the pain management service complejo hospitalario de vigo to the sars-cov-2 pandemic
Revista de la Sociedad Espanola del Dolor, Vol. 27
-
First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676
-
SEOM clinical guideline for management of adult medulloblastoma (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947
2020
-
Global gene expression characterization of circulating tumor cells in metastasic castration-resistant prostate cancer patients
Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-14
-
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
Annals of Oncology, Vol. 31, Núm. 6, pp. 780-788
2017
-
Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients
Oncotarget, Vol. 8, Núm. 33, pp. 54708-54721
2016
-
Clinical application of circulating tumour cells in prostate cancer: From bench to bedside and back
International Journal of Molecular Sciences, Vol. 17, Núm. 9
-
Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer
Scientific Reports, Vol. 6
2014
-
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer
International Journal of Cancer, Vol. 135, Núm. 11, pp. 2633-2643
-
Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment
Cancers, Vol. 6, Núm. 1, pp. 153-165
-
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer
Molecular Cancer, Vol. 13, Núm. 1
2013
-
Zoledronic acid as an antimetastatic agent for different human tumor cell lines
Anticancer Research, Vol. 33, Núm. 12, pp. 5295-5300
2012
-
A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer
Journal of Cellular and Molecular Medicine, Vol. 16, Núm. 10, pp. 2342-2349
-
Association of breast cancer and obesity in a homogeneous population from Spain
Journal of Endocrinological Investigation, Vol. 35, Núm. 7, pp. 681-685